Clinical Trials Directory

Trials / Completed

CompletedNCT03874585

Text Messaging-Based Smoking Cessation Program for Homeless Youth

Status
Completed
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
77 (actual)
Sponsor
RAND · Academic / Other
Sex
All
Age
18 Years – 25 Years
Healthy volunteers
Accepted

Summary

Unaccompanied homeless youth smoke at much higher rates than non-homeless adolescents and young adults. Many homeless youth smokers are motivated to quit; yet, strategies specifically developed for this vulnerable population are lacking. This study will develop and pilot test a text messaging intervention (also known as a TMI) to help homeless youth quit smoking. Text messaging can provide ongoing support for homeless youth during a quit attempt, which is important given that these youth tend to be highly mobile and lack regular access to health services. Participants in this study will be homeless youth who currently smoke and are motivated to quit smoking. All participants will receive a 30-minute group-based smoking cessation counseling session and a nicotine replacement product. Half of these smokers will also receive the TMI, for 6 weeks following the group counseling session, which will provide ongoing support for quitting. The main goal of this study is to investigate whether receiving the TMI results in greater reductions in cigarette smoking over a 3-month period compared to receiving the group counseling session alone.

Conditions

Interventions

TypeNameDescription
BEHAVIORALGroup counseling and nicotine replacementParticipants will receive a 30-minute group smoking cessation counseling session and a supply of nicotine replacement.
BEHAVIORALGroup counseling, nicotine replacement, and text messaging supportParticipants will receive a 30-minute group smoking cessation counseling session, a supply of nicotine replacement, and the 6-week text messaging intervention to provide ongoing support for quitting

Timeline

Start date
2019-05-30
Primary completion
2020-05-21
Completion
2020-05-21
First posted
2019-03-14
Last updated
2020-07-22

Locations

3 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT03874585. Inclusion in this directory is not an endorsement.